Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Amgen has appealed the European Medicines Agency (EMA) for the re-evaluation of the negative opinion issued by the Committee For Medicinal Products for Human Use (CHMP) for the use of Vectibix in combination with chemotherapy for patients who are suffering from wild-type KRAS metastatic colorectal cancer (mCRC).
Subscribe to our email newsletter
Amgen claims that Vectibix, in conjuction with chemotherapy, offers an an important treatment option for patients with wild-type KRAS mCRC.
Accoding to the company, the results from the studies 20050203 (PRIME) and 20050181 (181) demonstrated that adding Vectibix to Folfox and Folfiri chemotherapy, showed improved progression-free survival (PFS) versus chemotherapy alone in patients with wild-type KRAS mCRC.
The trials proved that the patients taking this combination have a greater chance of living longer without their disease getting worse.